FDA Eases Biosimilar PK Regulations and Expands Reference Product Acceptance
Portfolio Expansion to 41 Products Planned by 2038

Celltrion announced on March 13 that it will immediately apply the latest guideline from the US Food and Drug Administration (FDA), which eases regulations on biosimilar development, to its ongoing pipeline. The company expects that this change will allow it to reduce clinical costs in the immuno-oncology segment by up to 25%.


Celltrion Set to Benefit from FDA Biosimilar Regulation Easing: "Clinical Costs Could Drop by Up to 25%" View original image

The FDA recently released the "Draft Q&A Guidance for Biosimilar Development, 4th Revision." This latest draft recommends streamlining pharmacokinetic (PK) testing for biosimilars typically conducted during Phase 1 clinical trials, provided that scientific requirements are met.


The key point is the relaxation of reference product requirements. Previously, companies seeking entry into the US market were required to conduct direct PK comparison studies with US-approved reference products. However, under the new draft, equivalence can now be recognized based on comparative clinical data using reference products approved outside the US. This guideline is currently in draft form.


Celltrion anticipates that, given the particularly high cost of reference drugs in the immuno-oncology segment, this regulatory change alone could reduce overall clinical trial costs by up to 25%. The company also explained that if the guideline, announced in October last year, which streamlines or exempts Phase 3 clinical trials, is applied together, development-stage cost savings will be even greater. There is already a real-world example: for Cosentyx (CT-P55), an autoimmune disease treatment, the number of patients enrolled in the Phase 3 clinical trial last month was reduced from 375 to 153.


Celltrion currently has 11 biosimilar products on the market and plans to build a total portfolio of 41 products by 2038. The accessible global market size is expected to exceed 400 trillion won, more than four times the 85 trillion won reported last year. Key disclosed pipeline assets include the autoimmune disease treatments Ocrevus (CT-P53), Cosentyx (CT-P55), and Taltz (CT-P52), as well as the oncology drugs Keytruda (CT-P51) and Darzalex (CT-P44). In addition, there are more than 20 pipeline products for which detailed information has not yet been disclosed.



A Celltrion representative stated, "Based on the cost savings achieved, we will further expand our pipeline and grow into a leading big pharma with unparalleled cost competitiveness in the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing